TerminatedPhase 2

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

Stopped: Not able to recruit participants

United States5 participantsStarted 2021-11-09

Plain-language summary

This study will help determine the effect of Glucagon Like Peptide-1 (GLP-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (T2DM)

Who can participate

Age range55 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of Type 2 Diabetes Mellitus * Postmenopausal female * Age \>55 years * Hemoglobin A1c between 7-10% within 6 months of the first visit. Exclusion Criteria: * Patients with type 1 Diabetes mellitus * Patients with a history of GLP-1 receptor agonist/DPP4 inhibitor use * eGFR \<30 ml/min in the last 3 months * Patients with a history of pancreatitis * Personal or family history of medullary thyroid cancer * Patients with a history of treatment with anti-osteoporosis agents * Documented secondary osteoporosis * Documented presence of prosthesis or devices in the spine * Unwilling or unable to consent

What they're measuring

Trabecular Bone Score

Timeframe: 12 months after index date

Trial details

NCT IDNCT04964388

SponsorUniversity of Mississippi Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-05-01

Results submitted2024-05-17

View on ClinicalTrials.gov More Osteoporosis, Postmenopausal trials